Loading...
•
Dec 31, 2025
Corcept Therapeutics Q4 2025 Earnings Report
Corcept Therapeutics reported its fourth quarter 2025 financial results, highlighting revenue growth despite operational transitions and providing 2026 guidance.
Key Takeaways
Corcept achieved record Q4 revenue of $202.1 million, an 11% increase year-over-year, driven by strong demand in its Cushing’s syndrome business. While net income decreased due to higher operating expenses and a transition to a new specialty pharmacy vendor, the company ended the year with a strong cash position and set ambitious 2026 revenue guidance.
Q4 2025 revenue reached $202.1 million, up from $181.9 million in the prior year period.
The company completed a transition to a new specialty pharmacy vendor to address previous capacity constraints.
Net income for the quarter was $24.3 million, down from $30.7 million in Q4 2024, impacted by increased SG&A expenses.
Corcept provided full-year 2026 revenue guidance of $900 million to $1,000 million, signaling significant expected growth.
Revenue by Segment
Forward Guidance
Corcept expects significant revenue growth in 2026, supported by the resolution of pharmacy capacity constraints and upcoming clinical milestones.
Positive Outlook
- Full year 2026 revenue guidance of $900 – $1,000 million.
- February 2026 is on track to be a record month for new patient starts.
- PDUFA date of July 11, 2026, for relacorilant in platinum-resistant ovarian cancer.
- Expected EMA approval for relacorilant in PROC by the end of 2026.
- Phase 3 trial of dazucorilant in ALS planned to start by mid-2026.
Challenges Ahead
- Capacity constraints at previous specialty pharmacy limited 2025 growth.
- Operational disruptions occurred in Q4 during the pharmacy transition.
- Received a Complete Response Letter (CRL) from the FDA for relacorilant in Cushing’s syndrome.
- Higher operating expenses leading to lower year-over-year net income.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...